In an adult with end‑stage renal disease on dialysis and bipolar disorder who is taking duloxetine 30 mg daily and sertraline 25 mg daily, how should these medications be managed?

Medication Management in Dialysis Patient with Bipolar Disorder

Critical Medication Issues

Both duloxetine and sertraline require immediate reassessment in this patient, as duloxetine is contraindicated in severe renal impairment/dialysis and the combination of two serotonergic agents creates significant risk for serotonin syndrome, particularly in the dialysis population. 1, 2

Duloxetine: Contraindicated in Dialysis

Duloxetine must be discontinued. The FDA label explicitly states to "avoid use in patients with severe renal impairment, GFR <30 mL/minute" and notes that "increased plasma concentration of duloxetine, and especially of its metabolites, occurred in patients with end-stage renal disease (requiring dialysis)." 1

• In patients with ESRD requiring dialysis, duloxetine exposure increases approximately 2-fold, with metabolite accumulation up to 9-fold higher than in patients with normal renal function 3
• The drug is not generally recommended for patients with creatinine clearance <30 mL/min 1, 3

Sertraline: Requires Dose Adjustment and Caution

Sertraline can be used in dialysis patients but requires careful monitoring and likely dose reduction from the current 25 mg daily. 4

• The FDA label states that "sertraline multiple dose pharmacokinetics appear to be unaffected by renal impairment," making it the preferred antidepressant option in this population 4
• However, critical safety concern: One study reported that 11 of 12 dialysis patients developed features of serotonin syndrome on sertraline 25 mg daily, with one case requiring intensive care and ventilatory support 2
• More recent systematic review evidence suggests sertraline may be effective and relatively safe in hemodialysis patients when used appropriately, though studies are limited 5, 6

Bipolar Disorder Management Considerations

The current regimen is inappropriate for bipolar disorder treatment. Neither duloxetine nor sertraline are indicated for bipolar disorder, and antidepressant monotherapy (or dual antidepressant therapy) can precipitate manic episodes.

• If lithium was previously used, it can be continued with dialysis using a thrice-weekly dosing schedule of 300-900 mg lithium carbonate administered after each dialysis session 7
• Discontinuing lithium in bipolar patients with CKD is associated with significantly higher relapse rates (61% vs 10%) and shorter time to mood episodes (HR 8.38) 8
• Alternative mood stabilizers that are safer in dialysis include valproate or certain atypical antipsychotics 9, 8

Recommended Management Algorithm

Immediate actions:

1. Discontinue duloxetine immediately due to contraindication in dialysis 1, 3

2. Evaluate for serotonin syndrome given the dual serotonergic therapy in a dialysis patient - monitor for agitation, confusion, tremor, hyperreflexia, diaphoresis, or autonomic instability 2

3. Reassess bipolar disorder treatment:

   • If patient has history of lithium use, consider restarting with post-dialysis dosing (300-900 mg three times weekly after dialysis sessions) with close monitoring of pre-dialysis lithium levels 7
   • If lithium is not an option, consider valproate or atypical antipsychotics appropriate for renal impairment 9, 8

4. For depression/anxiety symptoms once mood stabilizer is established:

   • If antidepressant is still needed, sertraline monotherapy at 25-50 mg daily may be considered, but start at 25 mg with close monitoring for serotonergic side effects 5, 6
   • Monitor closely for the first 2-3 weeks for signs of serotonin toxicity 2

Monitoring parameters:

• Pre-dialysis drug levels if using lithium (target 0.6-1.0 mEq/L) 7
• Mental status changes, mood episodes, and serotonergic symptoms 2, 8
• Coordinate care between nephrology and psychiatry given the complexity 10